Ⓐ
PeptiBrief
Evidence Library
randomized_clinical_study · 1999

The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus

Nyholm B|Orskov L|Hove KY|Gravholt CH|Moller N|Alberti KG|Moyses C|Kolterman O|Schmitz O · Metabolism
moderateDOI · 10.1016/s0026-0495(99)90232-9PMID · 10421239Verified
View source
Plain-English summary

Pramlintide reduced post-meal glucose and glucagon responses when added to insulin.

Population
Adults with type 1 diabetes mellitus
Intervention
Subcutaneous pramlintide with insulin
Outcomes measured
Postprandial glucose|Glucagon|Gastric emptying
Key findings
Demonstrated clinically relevant amylin-receptor effects.
Limitations
Small short-term study|Requires insulin adjustment|Does not generalise to unlicensed analogues or obesity self-use
Risk of bias
Moderate — controlled clinical pharmacology study.
Citation
Nyholm B|Orskov L|Hove KY|Gravholt CH|Moller N|Alberti KG|Moyses C|Kolterman O|Schmitz O (1999). The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism. https://doi.org/10.1016/s0026-0495(99)90232-9
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.